Abstract:OBJECTIVE: We previously reported that primordial follicle (PMF) counts were significantly decreased in cyclophosphamide-treated mice when compared to mice receiving pretreatment with a GnRH-antagonist. However, serum AMH levels did not correlate with this finding. In the current analysis, we used a larger sample size to reexamine the use of AMH as a marker for PMF counts in a murine model of fertility preservation using a GnRH-antagonist prior to chemotherapy.DESIGN: Experimental murine study.MATERIALS AND METHODS: Serum was analyzed from 68 Balb/c female mice, aged 6 weeks. Groups 1 and 2 received a single intraperitoneal (IP) dose of 0.1 mL saline on study day 9. Groups 2, 4, and 6 received antagonist 0.5 mg/kg on study days 1-15. Groups 3 and 4 received 75 mg/kg of cyclophosphamide (CYC) and groups 5 and 6 received 100 mg/kg of CYC IP on study day 9. On study day 16, all mice were sacrificed. AMH levels were determined using a human AMH ELISA assay. Two-way ANOVA and T-tests with Bonferroni adjustment were used for statistical analysis.Tabled 1Serum AMH levels in mice treated with cyclophosphamide or control with or without GnRH-antagonistGroupNMeanSDMinMax1. Control125.211.283.928.202. Ant Only88.763.014.2913.473. CYC 75126.782.444.6313.744. CYC 75 + ANT126.251.464.258.615. CYC 100126.593.383.0116.226. CYC 100 + ANT126.711.704.499.66Ant (GnRH-antagonist), CYC (Cyclophosphamide) Open table in a new tab CONCLUSION: AMH levels were not different in mice receiving control compared to cyclophosphamide with or without antagonist pretreatment. AMH is not a marker for cyclophosphamide-induced destruction of PMF in mice. OBJECTIVE: We previously reported that primordial follicle (PMF) counts were significantly decreased in cyclophosphamide-treated mice when compared to mice receiving pretreatment with a GnRH-antagonist. However, serum AMH levels did not correlate with this finding. In the current analysis, we used a larger sample size to reexamine the use of AMH as a marker for PMF counts in a murine model of fertility preservation using a GnRH-antagonist prior to chemotherapy. DESIGN: Experimental murine study. MATERIALS AND METHODS: Serum was analyzed from 68 Balb/c female mice, aged 6 weeks. Groups 1 and 2 received a single intraperitoneal (IP) dose of 0.1 mL saline on study day 9. Groups 2, 4, and 6 received antagonist 0.5 mg/kg on study days 1-15. Groups 3 and 4 received 75 mg/kg of cyclophosphamide (CYC) and groups 5 and 6 received 100 mg/kg of CYC IP on study day 9. On study day 16, all mice were sacrificed. AMH levels were determined using a human AMH ELISA assay. Two-way ANOVA and T-tests with Bonferroni adjustment were used for statistical analysis. Ant (GnRH-antagonist), CYC (Cyclophosphamide) CONCLUSION: AMH levels were not different in mice receiving control compared to cyclophosphamide with or without antagonist pretreatment. AMH is not a marker for cyclophosphamide-induced destruction of PMF in mice.

Serum anti-mullerian hormone levels do not correlate with cyclophosphamide-induced primordial follicular destruction in mice pretreated with cetrorelix